Nuvisan GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Nuvisan GmbH is conducting research aimed at improving treatment options for pulmonary hypertension linked to left‑heart disease, focusing on safety and how new compounds behave in the body.
- Pulmonary hypertension due to left heart disease
- Evaluation of cardiovascular safety profiles
- Pharmacokinetic and pharmacodynamic assessments
- Early‑phase safety and tolerability studies
These efforts support the development of innovative cardiovascular therapies and help refine dosing strategies for patients with heart‑related conditions.
Hormonal Diseases
The clinical services team is exploring new approaches to manage vasomotor symptoms that arise from sex‑hormone fluctuations in both women and men, with an emphasis on efficacy and patient comfort.
- Vasomotor symptom relief strategies
- Hormone‑modulating agent evaluation
- Safety monitoring of hormone‑related treatments
- Quality‑of‑life impact assessments
By targeting hormone‑dependent disorders, Nuvisan aims to broaden therapeutic choices for individuals experiencing disruptive hot flashes and related signs.
Nervous System Diseases
Investigations at the site include studies on migraine, seeking to determine how emerging compounds can reduce attack frequency and improve patient outcomes while confirming safety.
- Migraine frequency reduction
- Neurological safety evaluation
- Pharmacodynamic profiling in healthy volunteers
- Early‑stage tolerability testing
These trials help pave the way for new migraine therapies that could offer relief to millions affected by this chronic neurological condition.
Pathological Conditions, Signs and Symptoms
Researchers are addressing severe systemic responses such as sepsis‑associated disseminated intravascular coagulation, aiming to identify interventions that can mitigate life‑threatening complications.
- Sepsis and DIC therapeutic evaluation
- Biomarker monitoring for coagulopathy
- Safety assessments in acute care settings
- Impact on organ function and recovery
The work contributes to a deeper understanding of critical illness pathways and supports the development of treatments that could improve survival rates.
General Pharmacology
A core focus at Nuvisan involves comprehensive drug‑drug interaction studies, evaluating how multiple agents behave together in healthy participants to ensure future combination therapies are safe and effective.
- Multi‑drug interaction profiling
- First‑in‑human safety and tolerability
- Pharmacokinetic mapping of novel compounds
- Cross‑over design assessments for absorption and clearance
These investigations lay the groundwork for combination regimens across therapeutic areas, helping to predict and prevent adverse effects before larger patient trials begin.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nuvisan GmbH
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of the Pharmacokinetics, Safety, and Tolerability of Epoetin Alfa Following Multiple Intravenous Doses in Healthy Male Participants | Blau Farmaceutica S.A. | Phase I | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ascorbic Acid | 1 | Unknown | 2023-09-28 | 2023-09-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.